Cervomed announces oral presentation at ctad 2023 highlighting learnings from phase 2a which optimized the design of the phase 2b clinical study of neflamapimod in dementia with lewy bodies

With incorporation of key learnings, phase 2b has >95% (approaching 100%) statistical power  to meet its primary endpoint: change in clinical dementia rating sum-of-boxes (cdr-sb) vs. placebo  new data included in the presentation show that in patients without alzheimer's-related co-pathology, neflamapimod treatment demonstrates significant reduction vs.
CRVO Ratings Summary
CRVO Quant Ranking